Fludarabine is a fluorinated nucleotide analog of adenosine, which is relatively resistant to deamination of adenosine deaminase. This medicine is an effective anti-tumor drug that may have obvious side effects. The blood system and non-hematological toxicity signs of patients should be closely monitored.
Mainly dose-dependent myelosuppression, such as neutropenia, anemia and so on. Other side effects include nausea, vomiting, diarrhea, anorexia, drug eruption, cough, and pneumonia. Serious can also cause blindness, death, and the like. Serious opportunistic infections have occurred in patients treated with fludarabine phosphate, and serious adverse events that have caused death have been reported.
747.3°C at 760 mmHg
Foil bag or cardboard drum
Cool,dry and hermetic place
For chronic lymphocytic leukemia
It is usually diluted with physiological saline. High doses can cause irreversible central nervous system toxicity such as late blindness, coma and death.
Peripheral blood cell counts are recommended for periodic testing to understand the progression of anemia, neutropenia, and thrombocytopenia. In adult patients, there are several cases of three-line bone marrow dysplasia or hypoplasia leading to pancytopenia, which can sometimes lead to death. The clinically significant cell reduction in the reported cases lasted approximately two months to one year.
Signs of hemolysis should be closely monitored in patients receiving this drug. Once hemolysis occurs, it is recommended to discontinue treatment with this medicine. Blood transfusion and application of adrenocortical hormone are the most commonly used methods for the treatment of autoimmune hemolytic anemia.